NEWS

• Crucial Data Solutions Expands TrialKit AI With Study Simulation And Validation Capabilities
• Health Equity Research Goes Global—Without Waiting For Perfect Data

  Value in Health Regional Issues published a special research collection showing meaningful progress in health equity across regions with varying data environments and policy needs.

• International Study Confirms Universal Digital Health Framework

  Value in Health published an international study showing the PICOTS‑ComTeC framework is an effective standard for defining patient-facing digital health interventions.

• Blinded Diagnostics To Participate In Global Multi-Center Clinical Trial Engagement

  Blinded Diagnostics has been engaged to provide point of care diagnostics services to support a global multi-center clinical trial.

• Spanish Biotech PharmaMar Selects Medidata Clinical Cloud To Accelerate Trials For Marine-Based Oncology Drugs

  PharmaMar, a Spanish biopharmaceutical company, has selected Medidata Solutions (NASDAQ: MDSO) for its industry-leading electronic data capture (EDC) and clinical data management (CDM), safety data capture and reporting, and medical coding solutions. A member of the Zeltia Group and a leader in the development of antitumor drugs of marine origin, PharmaMar said the company’s investment in the Medidata Clinical Cloud™ will efficiently streamline its clinical trial processes in its mission to deliver drugs that treat cancer and rare ("orphan") diseases.

• Lithera Initiates Phase 2b Clinical Trial Of LIPO-202 Targeting Aesthetic Reduction Of Subcutaneous Abdominal Fat

  Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.

• Telormedix Enrols First Patient For Phase II In Bladder Cancer

  Telormedix, a clinical stage biopharmaceutical company focusing on toll-like receptor 7 (TLR7) small molecules in the treatment of cancer and inflammatory diseases, recently announced that it has recruited the first patient in a Phase II trial of its lead product TMX-101, a TLR-7 agonist, in carcinoma in situ (CIS) in the bladder.

• Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial

  Concert Pharmaceuticals, Inc. announced today that it has completed enrollment of patients in a Phase 2 clinical trial evaluating CTP-499 for the treatment of diabetic kidney disease. CTP-499 is intended to slow progression of kidney damage in diabetic kidney disease and be additive to the current standard of care, which is treatment with an angiotensin converting enzyme inhibitor (ACEi) and/or an angiotensin receptor blocker (ARB). Concert expects to report top-line results from the Phase 2 study during the second-half of 2013.

• DiaMedica Successfully Completes DM-199 cGMP Manufacturing And Pre-Clinical Toxicology Safety Studies

  DiaMedica (TSX VENTURE:DMA) has successfully completed cGMP manufacturing of DM-199 to be utilized in upcoming clinical trials.

• Amgen Announces Top-Line Results Of Phase 3 Aranesp® (darbepoetin alfa) RED-HF® Trial

  Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 Aranesp^® (darbepoetin alfa) RED-HF^® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

• GeoVax Announces Enrollment Completion For Phase 1/2 Clinical Trial For HIV/AIDS Therapeutic Vaccine

  GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, announced it has completed enrollment in a nine-patient Phase 1/2 clinical trial testing the safety, immunogenicity and ability of its DNA/MVA vaccine to elicit protective immune responses in HIV-infected individuals.

• Blinded Diagnostics Appoints Patricia H. Averette As VP, Business Development

  Blinded Diagnostics announced the expansion of their business development efforts by appointing Patricia H. Averette, a seasoned health care professional with a solid background in Hematology Lab Diagnostics, as the new Vice President of Business Development. 

• Thomson Reuters Spotlights The Impact Of Personalized Medicine On Pharmaceutical R&D

  The IP & Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced the publication of a new report that provides a comprehensive view of the potential effects of personalized medicine on drug research and development.

• PHT Corporation Patents 'Time Travel' For Clinical Research

  It’s now possible for clinical trial researchers to control time, thanks to PHT Corporation’s patented Time Travel technology.PHT is the world’s leading provider of systems used to collect patient-driven eData for clinical research.